Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03048084 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Seizure Treatment in Glioma

Study acronym: STING
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 6 months later Jul 1, 2026 → Jan 1, 2028
See other at-risk trials from Leiden University Medical Center

Record History

  1. Primary completion pushed from Jul 1, 2026 to Jan 1, 2028 Completion pushed from Jul 1, 2028 to Jul 1, 2029 · Secondary endpoints: 12 to 13v7 Show 2 more changesShow less
    • Completion pushed from Jul 1, 2028 to Jul 1, 2029
    • Secondary endpoints: 12 to 13

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Jan 1, 2026 to Jul 1, 2026 Completion date: Jan 1, 2028 to Jul 1, 2028 · Study sites revised (5)v6 Show 2 more changesShow less
    • Completion date: Jan 1, 2028 to Jul 1, 2028
    • Study sites revised (5)

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv5
  4. Primary completion date: Jan 1, 2025 to Jan 1, 2026 Study sites: 4 to 5 · Completion date: Jan 1, 2027 to Jan 1, 2028 · Secondary endpoints revised (12)v4 Show 3 more changesShow less
    • Study sites: 4 to 5
    • Completion date: Jan 1, 2027 to Jan 1, 2028
    • Secondary endpoints revised (12)

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: Feb 1, 2021 to Jan 1, 2025 Completion date: Feb 1, 2022 to Jan 1, 2027 · Site details revised at 2 of 4 sitesv3 Show 2 more changesShow less
    • Completion date: Feb 1, 2022 to Jan 1, 2027
    • Site details revised at 2 of 4 sites
  6. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Dec 2018 to Feb 1, 2021 · Start date changed from estimate of Jun 1, 2017 to Feb 1, 2018 · Completion date: Jun 2021 to Feb 1, 2022 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Dec 2018 to Feb 1, 2021
    • Start date changed from estimate of Jun 1, 2017 to Feb 1, 2018
    • Completion date: Jun 2021 to Feb 1, 2022
    • Eligibility criteria shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Currently, treatment with a specific anti-epileptic drug mainly depends on the physicians' preference, as there are no studies supporting the use of one specific anticonvulsant in glioma patients. The overall aim of this randomized controlled trial is to directly compare the effectiveness of treatment with levetiracetam or valproic acid in glioma patients with a first seizure.
Trial Details
NCT Number NCT03048084
Lead Sponsor Leiden University Medical Center
Collaborators: Medical Center Haaglanden, Erasmus Medical Center, Amsterdam UMC, location VUmc
Conditions Glioma
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov